Abstract:Objective: Aldosterone is related to the fibrosis of several organs, but the specific mechanism underlying the aldosterone induced hepatic fibrosis is still unclear. Methods: Separation, culture and identification of primary hepatic stellate cells (HSCs): The fluids and digestives used in the present study were able to completely remove blood cells, digest hepatocytes and matrix, and effectively separate HSCs. The in situ perfusion was performed at 2 steps: in situ perfusion with pre-perfusion fluid and ex vivo perfusion with enzyme-containing perfusion fluid. Influence of Ald on PAI-1 and Smad expressions in HSCs: cells were divided into control group, Ald group (10(-6) M), spironolactone (SPI) group and Ald+SPI group, and the mRNA and protein expressions of PAI-1 and Smad were detected. Ald induced type I collagen expression in HSCs: Immunohistochemistry was performed to detect type I collagen expression in the supernatant of control group, Ald group (10(-6) M), TGF-beta(1) group, and Ald+TGF-beta(1) group. Influence of Ald and TGF-beta(1) on PAI-1 expression in HSCs: cells were divided into control group, Ald group (10(-6) M), TGF-beta(1) group, and Ald+TGF-beta(1) group, and the mRNA and protein expressions of PAI-1 were determined by RT-PCR and Western blot assay, respectively. Synergistic effect of Ald and TGF-beta(1) on PAI-1 expression in HSCs: cells were divided into control group, Ald group (10(-6)), TGF-beta(1) group, Ald (10(-6) M)+TGF-beta(1) group, Ald (10(-7) M)+TGF-beta(1) group and Ald (10(-8) M)+TGF-beta(1) group, and the mRNA and protein expressions of PAI-1 were detected by RT-PCR and Western blot assay, respectively. Results: The survival rate, purity, markers and activation of HSCs were determined after separation. Influence of Ald on PAI-1 expression in HSCs: PAI-1 expression increased in HSCs of Ald group, SPI group and Ald+API group, and the PAI-1 expression in Ald group and Ald+SPI group was significantly higher than in control group (P<0.01). Influence of Ald on Smad expression in HSCs: Smad expression in Ald group, TGF-beta(1) group and ALD+TGF-beta(1) group was markedly higher than in control group (P<0.05). Smad expression in ALD+TGF-beta(1) group increased significantly when compared with Ald group (P<0.01). Ald induced type I collagen expression in HSCs: type I collagen expression in Ald group, TGF-beta(1) group and ALd+TGF-beta(1) group was dramatically higher than in control group (P<0.05), and it in ALd+TGF-beta(1) group was also significantly different from that in Ald group and TGF-beta(1) group (P<0.01). Synergistic effects of Ald and TGF-beta(1) on PAI expression in HSCs: PAI-1 expression in treated cells was markedly higher than in control group (P<0.01). PAI-1 expression in 10(-6) M Ald+5 ng/ml TGF-beta(1) group increased dramatically as compared to Ald group and TGF-beta(1) group (P<0.01), but the increased PAI-1 expression reduced after SPI treatment. Ald at different concentrations exerts synergistic effect with TGF-beta(1) to increase PAI-1 expression in HSCs: PAI-1 expression in HSCs after different treatments increased markedly as compared to control group (P<0.01).Significant difference in PAI-1 expression was observed in 10(-6) M Ald+50 pg/ml TGF-beta(1) group and 10(-6) M Ald group (P<0.01), PAI-1 expression in 10(-7) M Ald+50 pg/ml TGF-beta(1) group was significantly higher than in 50 pg/ml TGF-beta(1) group (P<0.01), but the PAI-1 expression in 10(-7) M Ald+50 pg/ml TGF-beta(1) group was similar to that in 10(-6) M Ald group (P>0.05). Conclusion: Aldosterone is able to activate HSCs and increase PAI-1 expression during hepatic fibrosis, which may be inhibited by spironolactone. Aldosterone and TGF-beta(1) may synergistically act on HSCs to increase PAI-1 expression as compared to treatment with aldosterone or TGF-beta(1) alone. Aldosterone or TGF-beta(1) alone may slightly increase PAI-1 expression in HSCs, which can be inhibited by spironolactone.

Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Aldosterone and aldosterone synthase inhibitors in cardiorenal disease

Discovery of Benzimidazole Derivatives as Novel Aldosterone Synthase Inhibitors: QSAR, Docking Studies, and Molecular Dynamics Simulation?

Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2

ACTHR in Regulating Aldosterone Secretion to Angiotensin Ⅱ and Potassium Chloride Stimulation

Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to attenuate hypertension

Aldosterone and TGF-β₁ Synergistically Increase PAI-1 Expression in Hepatic Stellate Cells of Rats.

CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers

LBODP025 A Novel Drug Discovery For Primary Aldosteronism Targeting Aldosterone Synthase (cyp11b2) And Kcnj5 Mutant

Inhibition of Aldosterone Biosynthesis by Staurosporine

Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.

Evaluating the role of aldosterone synthesis on adrenal cell fate

Discovery of Novel, Potent and Low-Toxicity Angiotensin Ii Receptor Type 1 (at(1)) Blockers: Design, Synthesis and Biological Evaluation of 6-Substituted Aminocarbonyl Benzimidazoles with A Chiral Center

Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10

Research and Development of Aldosterone Inhibitors